Monitoring of unfractionated heparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent (PiCT®)

Clinica Chimica Acta

Volumn 414, Issue , 2012, Pages 202-205

  Schaden, E ^a   Jilch, S ^a   Hacker, S ^a   Schober, A ^a   Kozek Langenecker, S ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Evangelical Hospital Vienna   (Austria)

Author keywords

Anticoagulant heparin; Blood coagulation tests; Partial thromboplastin time; Thrombelastography

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; HEPTEM; INTEM; PICT; ROTEM; THROMBOPLASTIN;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADULT; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL ARTICLE; CORRELATION COEFFICIENT; CORRELATIONAL STUDY; DRUG DOSE ESCALATION; DRUG MONITORING; FEMALE; HEMOSTATIC TECHNIQUE; HUMAN; IN VITRO STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; BLOOD; BLOOD CLOTTING TEST; METABOLISM; REFERENCE VALUE; ROTATION; SENSITIVITY AND SPECIFICITY; THROMBOELASTOGRAPHY;

ADULT; BLOOD COAGULATION TESTS; FEMALE; HEPARIN; HUMANS; MALE; REFERENCE VALUES; ROTATION; SENSITIVITY AND SPECIFICITY; THROMBELASTOGRAPHY; THROMBOPLASTIN;

EID: 84867284255     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.09.029     Document Type: Article

References (17)

1. Hirsh, J., Guyatt, G., Albers, G.W., Harrington, R., Schünemann, H.J., American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008), 110S–112S.
2. Levine, M.N., Hirsh, J., Gent, M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154 (1994), 49–56.
3. Schaden, E., Schober, A., Hacker, S., Spiss, C., Chiari, A., Kozek-Langenecker, S., Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent. Blood Coagul Fibrinolysis 21 (2010), 256–261.
4. http://www.oegari.at/dateiarchiv/205/guidelines (english version.pdf).
5. Pfanner, G., Koscielny, J., Pernerstorfer, T., et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist 56 (2007), 604–611.
6. Basu, D., Gallus, A., Hirsh, J., Cade, J., A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 287 (1972), 324–327.
7. Luddington, R.J., Thrombelastography/thrombelastometry. Clin Lab Haematol 27 (2005), 81–90.
8. Lang, T., Bauters, A., Braun, S.L., et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 16 (2005), 301–310.
9. Mittermayr, M., Margreiter, J., Velik-Salchner, C., et al. Effects of heparin and protamin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth 95 (2005), 310–316.
10. Konstantinidis, K., Gerasimidis, T., Verdy, E., Elalamy, I., Samama, M.M., Gerotziafas, G.T., Inhibition of clot formation process by treatment with the low molecular weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting (Trans.) A thrombelastography study on whole blood Thromb Haemost 97 (2007), 109–118.
11. Sörensen, B., Johansen, P., Christiansen, K., Woelke, M., Ingerslev, J., Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1 (2003), 551–558.
12. Eikelboom, J.W., Hirsh, J., Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 96 (2006), 547–552.
13. Baker, B.A., Adelman, M.D., Smith, P.A., Osborn, J.C., Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 157 (1997), 2475–2479.
14. Uprichard, J., Manning, R.A., Laffan, M.A., Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 149 (2010), 613–619.
15. Calatzis, A., Peetz, D., Haas, S., Spannagl, M., Rudin, K., Wilmer, M., Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 130 (2008), 446–454.
16. Ay, C., Dunkler, D., Simanek, R., et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29 (2011), 2099–2103.
17. http://www.rotem.de (last access 07/04/2012).